Kos Biotechnology Partners has invested in Golden Age Health through its inaugural fund, Kos BioVentures. The investment firm manages $125 million in assets across New York and Athens. Alex Tzoukas will join the Golden Age Health board of directors.
Expansion plans
The investment will support Golden Age Health's commercial expansion in Greater China and Asia-Pacific. It is also meant to accelerate the cross-border flow of biotech innovation between Western markets and Asia. Kos will help scale the company's commercial footprint and portfolio.
Company background
Golden Age Health was co-founded in 2023 by Michel Vounatsos, Yossi Ben Amram, and Reda Rebib. Vounatsos is the former chief executive officer of Biogen. The company is headquartered in Singapore.
What Golden Age Health offers
Golden Age Health partners with Western and Asian biopharma companies to bring approved or near-approved rare disease therapies to patients. It provides regulatory strategy, market access, commercialization, and real-world evidence services. Its commercial models range from distribution and promotion to profit-share and in-licensing.
Alex Tzoukas will work with the leadership team to strengthen governance during the next growth stage. Golden Age Health plans to scale its portfolio of approved rare disease medicines in Greater China and Asia-Pacific. It also aims to bring high-potential Asian biotech innovation into Western clinical pipelines.